Clinical Utility of ctDNA in the Treatment of Oligometastatic Disease

October 1, 2026 updated by: Louise Bach Callesen, Aarhus University Hospital

Clinical Utility of ctDNA in the Treatment of Oligometastatic Disease - A Prospective Observational Clinical Study - A Part of the POB-project

This prospective observational study investigates the clinical utility of circulating tumor DNA (ctDNA) in patients with oligometastatic disease (OMD) undergoing definitive-intent local ablative treatment (LAT). The study aims to evaluate ctDNA as a prognostic and response biomarker before, during, and after LAT across cancer types and treatment modalities. Serial plasma samples and archival tumor tissue will be analyzed to assess ctDNA detection rates, elimination patterns, minimal residual disease, and association with recurrence, progression, and survival outcomes.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Oligometastatic disease (OMD) represents an intermediate disease state between localized and polymetastatic cancer and may be amenable to curative or long-term disease-controlling local ablative treatment (LAT). Despite careful patient selection, recurrence rates after LAT remain substantial, highlighting the need for improved biological markers to guide treatment decisions and follow-up.

Circulating tumor DNA (ctDNA) is a promising biomarker for prognostication, response assessment, and early detection of recurrence. Pilot studies and systematic reviews conducted by the study group indicate that ctDNA dynamics before and after LAT are associated with treatment outcomes. However, important knowledge gaps remain regarding ctDNA detection rates, elimination patterns, optimal sampling time points, and clinical relevance across metastatic sites, treatment modalities, and oligometastatic states.

This prospective observational study, conducted as part of the Pan-Cancer Oligometastatic Biology (POB) project, will enroll patients with oligometastatic solid tumors planned for definitive-intent LAT. Serial blood samples will be collected before treatment, during treatment when applicable, and throughout follow-up. ctDNA and total circulating free DNA will be analyzed using sensitive molecular techniques. Archival tumor tissue will be retrieved for tumor-informed analyses.

The study will evaluate ctDNA detection rates, elimination patterns, minimal residual disease, lead time to radiological recurrence, and associations with disease-free survival, progression-free survival, and overall survival. Exploratory analyses of immune-related biomarkers will also be performed. The results are expected to support improved biological stratification and monitoring strategies in oligometastatic disease.

Study Type

Observational

Enrollment (Estimated)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Louise B Callesen, MD, PhD
  • Phone Number: 30482884
  • Email: Louicall@rm.dk

Study Contact Backup

Study Locations

      • Aarhus N, Denmark, 8200
        • Recruiting
        • Department of Oncology, Aarhus University Hospital
        • Contact:
          • Louise B Callesen, MD, PhD
          • Phone Number: 30482884
          • Email: Louicall@rm.dk
        • Principal Investigator:
          • Louise B Callesen, MD, PhD
        • Principal Investigator:
          • Karen-Lise G Spindler, Professor, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The study population consists of patients with verified oligometastatic cancer disease who are planned for local ablative therapy.

Description

Inclusion Criteria:

  • Metastatic spread from histopathological diagnosed solid cancer
  • Planned for LAT (local ablative therapy) for OMD (oligometastatic disease)
  • ≥ 18 years
  • Written and oral consent

Exclusion Criteria:

  • Other cancer disease within 5 years
  • Conditions that will contraindicate blood samples

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Association between longitudinal ctDNA status and clinical outcomes after local ablative treatment
Time Frame: During follow-up up to 5 years

Presence and dynamics of circulating tumor DNA (ctDNA) assessed before LAT, after LAT, and during follow-up, and their association with clinically relevant outcomes including radiologically confirmed recurrence or progression, survival status, and lead time to recurrence.

During follow-up up to 5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Detection rate of ctDNA prior to local ablative treatment
Time Frame: Baseline (pre-LAT)

The proportion of patients with detectable circulating tumor DNA in plasma prior to initiation of local ablative treatment will be assessed. Detection rates will be evaluated overall and stratified by treatment modality, cancer type and metastatic site

Baseline (pre-LAT)
Elimination patterns of ctDNA following local ablative treatment
Time Frame: During follow-up up to 5 years

Changes in ctDNA levels following local ablative treatment will be analyzed to characterize elimination patterns over time. Changes in ctDNA will be assessed in relation to treatment modality, cancer type, metastatic site, and timing of sampling to evaluate biological response to treatment

During follow-up up to 5 years
Correlation between ctDNA and pathological response
Time Frame: During follow-up up to 5 years

ctDNA status and ctDNA changes will be correlated with pathological response

During follow-up up to 5 years
Correlation between ctDNA and risk of recurrence or early progression
Time Frame: Up to 5 years

The association between ctDNA and the subsequent risk of recurrence or early disease progression will be evaluated

Up to 5 years
Correlation between ctDNA and disease-free survival or progression-free survival
Time Frame: Up to 5 years

Disease-free survival or progression-free survival will be analyzed according to ctDNA status at baseline, post-treatment, and during follow-up to assess the prognostic value of ctDNA in patients treated with definitive-intent local ablative treatment

Up to 5 years
Correlation between ctDNA and overall survival
Time Frame: Up to 5 years

Overall survival will be analyzed according to ctDNA status at baseline, post-treatment, and during follow-up to assess the prognostic value of ctDNA in patients treated with definitive-intent local ablative treatment

Up to 5 years
Rate of ctDNA-detected minimal residual disease
Time Frame: up to 5 years

The proportion of patients with detectable ctDNA following completion of definitive-intent local ablative treatment, consistent with molecular minimal residual disease, will be determined and analyzed in relation to clinical outcomes

up to 5 years
Lead time between ctDNA detection and imaging-confirmed recurrence or progression
Time Frame: During follow-up up to 5 years

The time interval between first detection of ctDNA during follow-up and subsequent radiological confirmation of recurrence or progression will be calculated to estimate the potential lead time provided by ctDNA monitoring

During follow-up up to 5 years
Exploratory analysis of total circulating free DNA
Time Frame: Up to 5 years

Total circulating free DNA levels will be quantified and analyzed exploratorily in relation to treatment, ctDNA status, imaging findings, and clinical outcomes to assess potential additional biological or prognostic value

Up to 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 17, 2026

Primary Completion (Estimated)

March 1, 2030

Study Completion (Estimated)

September 1, 2030

Study Registration Dates

First Submitted

January 29, 2026

First Submitted That Met QC Criteria

February 16, 2026

First Posted (Actual)

February 23, 2026

Study Record Updates

Last Update Posted (Actual)

October 5, 2026

Last Update Submitted That Met QC Criteria

October 1, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 1-10- 72-122-25

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.